Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diseases of the Genitourinary System Clear all
Completed Phase 3 Interventional Results available

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

NCT01358760
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

NCT04703920
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
Interventions
Talazoparib, Belinostat
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 3 Interventional

Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo

NCT01064024
View directory record Official record
Conditions
Pain, Urinary Tract Infections
Interventions
Phenazopyridine Hydrochloride, Placebo
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Totowa, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional

Hula, a Physical Activity Intervention for Female-Cancer Survivors

NCT02351479
View directory record Official record
Conditions
Physical Activity, Breast Cancer, Cervical Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Hula
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
21 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 23, 2026, 6:06 AM EDT
Terminated Phase 1 Interventional

Robotic Seed Implantation for Prostate Cancer Brachytherapy

NCT01341288
View directory record Official record
Conditions
Prostate Cancer
Interventions
EUCLIDIAN Robot
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
40 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Results available

Acupuncture for Urinary Incontinence

NCT00297427
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Acupuncture, Sham acupuncture
Procedure · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years and older · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing Rectal USPE Measures for Suppositories (Project DRUM-S)

NCT02744261
View directory record Official record
Conditions
Microbicide Delivery System Perceptibility and Acceptability
Interventions
Gel, Suppository 1, Suppository 2
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Completed No phase listed Observational

Patient Satisfaction Survey of Non-surgical Urinary Incontinence Treatment

NCT04064970
View directory record Official record
Conditions
Urinary Incontinence
Interventions
patient acceptable symptom state (PASS)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jul 23, 2026, 6:06 AM EDT
Terminated Phase 4 Interventional Results available

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Lopinavir/Ritonavir, Truvada
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

NCT00002142
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 6:06 AM EDT
Active, not recruiting Early Phase 1 Interventional

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

NCT03943173
View directory record Official record
Conditions
BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Chemotherapy, Olaparib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

NCT03324373
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Partial or Radical Cytoreductive Nephrectomy
Drug · Procedure
Lead sponsor
Yousef Zakharia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Completed No phase listed Observational

Delivery Room Practice Change Following the Initiation of the NICHD SUPPORT Trial

NCT01601886
View directory record Official record
Conditions
Preterm Birth
Interventions
Not listed
Lead sponsor
Luc Brion
Other
Eligibility
24 Weeks to 35 Weeks
Enrollment
3,843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Jul 23, 2026, 6:06 AM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Completed No phase listed Observational

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer

NCT01471483
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
geriatric assessment and telephone call from nurse, geriatric assessment and no call from nurse
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
3
States / cities
Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Terminated Phase 1 Interventional

Psychosocial Benefits of Exercise in Endometrial Cancer Survivors

NCT01401829
View directory record Official record
Conditions
Endometrial Cancer
Interventions
150 weekly minutes walking, 75 weekly minutes walking, Stretching/Flexibility exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 23, 2026, 6:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Guilford Genomic Medicine Initiative (GGMI)

NCT01372553
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
Interventions
Not listed
Lead sponsor
The Moses H. Cone Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
1,184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)

NCT00907153
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Vitamin D, Placebo
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional

Treatment Choice and Outcomes for ESRD: Evidence From the First Year of a Nationwide Randomized Evaluation

NCT05005572
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Payment adjustment for home dialysis and transplant
Other
Lead sponsor
Amy Finkelstein
Other
Eligibility
66 Years and older
Enrollment
18,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 23, 2026, 6:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180
View directory record Official record
Conditions
Cervical Cancer
Interventions
Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
38
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 6:06 AM EDT
Withdrawn No phase listed Observational

Identification of Risk Allels for Prostate Cancer

NCT00323388
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 23, 2026, 6:06 AM EDT
Enrolling by invitation Not applicable Interventional

Families Moving Forward Bridges: An Early Intervention for Infants and Toddlers With PAE With or At-risk for FASD

NCT06935461
View directory record Official record
Conditions
Prenatal Alcohol Exposure, Fetal Alcohol Spectrum Disorders
Interventions
Families Moving Forward Bridges
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
6 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Shoreline, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Completed Not applicable Interventional Results available

Improving Treatment and Retention Adherence in Nontraditional Settings

NCT04973254
View directory record Official record
Conditions
HIV Infections
Interventions
CAB-RPV LA, Standard treatment within an HIV clinic
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 23, 2026, 6:06 AM EDT
Completed No phase listed Observational

Bladder Antimuscarinic Medication and Accidental Bowel Leakage

NCT03543566
View directory record Official record
Conditions
Urinary Incontinence, Urge, Fecal Incontinence
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jul 23, 2026, 6:06 AM EDT